TB-500 is a synthetic analogue of Thymosin Beta-4, a ubiquitous 43-amino acid peptide involved in actin sequestration, angiogenesis, and wound healing. This article reviews the research literature on its mechanisms and studied biological effects.
TB-500 is not Thymosin Beta-4 itself — it is a fragment. The two are routinely conflated.
Thymosin Beta-4 (TB4) is a 43-amino acid, 4.96 kDa peptide originally isolated from thymic tissue but subsequently found to be ubiquitously expressed in virtually all mammalian cells. It is encoded by the TMSB4X gene and is one of the most abundant peptides in eukaryotic cells, with cytoplasmic concentrations in the micromolar range in many tissue types (Goldstein, Hannappel, and Kleinman, 2005).
TB-500, the synthetic research analogue, replicates the amino acid sequence of Thymosin Beta-4. The compound is supplied as a lyophilised acetate salt and reconstituted with bacteriostatic water for research use.
Molecular Formula (TB-500): C212H350N56O78S
CAS Number: 77591-33-4
Molecular Weight: 4963.4 Da
The best-characterised function of Thymosin Beta-4 is G-actin (globular actin) sequestration. Actin exists in two states: monomeric G-actin and filamentous F-actin. Dynamic polymerisation and depolymerisation of actin is fundamental to cell migration, division, and tissue remodelling. Thymosin Beta-4 binds G-actin monomers in a 1:1 ratio with high affinity (Kd approximately 0.5 microM), effectively buffering the pool of polymerisable actin (Safer, Bhatt, and Bhatt, 1991).
By regulating the availability of G-actin, TB4 modulates the rate and direction of actin polymerisation. This function places it at the intersection of cell motility, wound healing, and angiogenesis, as each of these processes is dependent on dynamic cytoskeletal remodelling.
The tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is an N-terminal fragment of Thymosin Beta-4 that is released by prolyl oligopeptidase cleavage. Ac-SDKP has independent biological activity and is considered to mediate a subset of TB4's effects on fibrosis, angiogenesis, and inflammation. Research on Ac-SDKP as a distinct molecule has grown alongside TB4 research, as it is more accessible for mechanistic studies due to its smaller size (Rhaleb et al., 2001).
One of the most extensively studied applications of Thymosin Beta-4 is its role in wound healing. Preclinical studies in rodent models have examined both full-thickness skin wounds and corneal injury.
In a standardised murine full-thickness wound model, topically applied TB4 accelerated wound closure by 41% compared to vehicle control, with enhanced granulation tissue formation, collagen deposition, and angiogenesis at the wound site (Malinda et al., 1999). The proposed mechanism involves TB4-mediated keratinocyte and endothelial cell migration, both of which are dependent on actin cytoskeletal dynamics.
Corneal wound healing research has produced particularly consistent results. Multiple studies using standardised corneal epithelial debridement models in rodents and rabbits found that TB4 eye drops significantly accelerated re-epithelialisation compared to controls. These findings led to Phase 2 clinical trials for dry eye disease (Kim et al., 2010).
Thymosin Beta-4 promotes angiogenesis through multiple mechanisms. In in-vitro tube formation assays, TB4 significantly enhanced endothelial cell tube formation and migration. In subcutaneous Matrigel plug assays in rodents, TB4-supplemented plugs showed substantially greater vascularisation than controls (Grant et al., 1999).
The proposed mechanisms include direct endothelial cell chemotaxis (via G-actin modulation enabling migration), upregulation of VEGF (vascular endothelial growth factor) expression, and Ac-SDKP-mediated endothelial proliferation. TB4 also promotes eNOS (endothelial nitric oxide synthase) expression, which may contribute to vasodilation in healing tissue.
A significant body of preclinical research has investigated TB4 in myocardial injury models. Studies in rodent models of myocardial infarction have reported that systemic TB4 administration:
Bock-Marquette et al. (2004) demonstrated that TB4 activates integrin-linked kinase (ILK), which mediates downstream Akt signalling in cardiomyocytes. This PI3K/Akt survival pathway was identified as a principal mechanism of the observed cardioprotective effects.
Skeletal muscle models have also been examined. Studies in rodent muscle laceration models found that TB4 administration accelerated satellite cell activation and muscle fibre regeneration, with reduced fibrosis in healed tissue compared to controls (Bedogni et al., 2010).
Thymosin Beta-4 has been reported to modulate inflammatory responses in several experimental models. Studies in rodent inflammation models demonstrate reduced neutrophil and macrophage infiltration at injury sites following TB4 administration. The proposed mechanisms include downregulation of NF-kappaB signalling and reduced expression of pro-inflammatory cytokines including IL-1 beta, TNF-alpha, and IL-6 (Sosne et al., 2010).
The anti-fibrotic activity of Ac-SDKP has been separately characterised. In models of cardiac and renal fibrosis, Ac-SDKP inhibited TGF-beta-induced fibroblast activation and collagen synthesis, an effect attributed to its role as an endogenous angiotensin-converting enzyme (ACE) substrate (Rhaleb et al., 2001).
| Research Area | Model | Key Findings |
|---|---|---|
| Wound healing | Murine full-thickness wound | 41% faster closure, enhanced granulation tissue |
| Corneal repair | Rodent/rabbit debridement | Significantly faster re-epithelialisation |
| Angiogenesis | In-vitro, Matrigel plug | Enhanced tube formation, increased vascularisation |
| Cardiac repair | Rodent MI models | Reduced infarct size, improved ejection fraction |
| Muscle repair | Rodent laceration model | Faster regeneration, reduced fibrosis |
| Inflammation | Multiple rodent models | Reduced cytokine expression and immune infiltration |
1. Goldstein AL, Hannappel E, Kleinman HK. "Thymosin Beta-4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues." *Trends in Molecular Medicine.* 2005;11(9):421-429.
2. Safer D, Bhatt E, Bhatt J. "The Primary Structure of Thymosin Beta-4 and Its Association with Actin." *Journal of Biological Chemistry.* 1991;266(8):4916-4921.
3. Malinda KM, Goldstein AL, Kleinman HK. "Thymosin Beta-4 Stimulates Directional Migration of Human Umbilical Vein Endothelial Cells." *FASEB Journal.* 1997;11(6):474-481.
4. Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, Kleinman H. "Thymosin Beta-4 Enhances Endothelial Cell Differentiation and Angiogenesis." *Angiogenesis.* 1999;3(2):125-135.
5. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. "Thymosin Beta-4 Activates Integrin-Linked Kinase and Promotes Cardiac Cell Migration, Survival and Cardiac Repair." *Nature.* 2004;432(7016):466-472.
6. Sosne G, Qiu P, Goldstein AL, Wheater M. "Biological Activities of Thymosin Beta-4 Defined by Active Sites in Short Peptide Sequences." *FASEB Journal.* 2010;24(7):2144-2151.
7. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. "Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on DNA and Collagen Synthesis in Rat Cardiac Fibroblasts." *Hypertension.* 2001;37(3):827-832.
Disclaimer: All information is based on published preclinical research literature and is provided for educational purposes only. TB-500 is sold strictly for in-vitro laboratory and research purposes. Not medical advice.
On 28 July 2026 the FDA released 17 revised draft product-specific guidances for generic peptide drugs — and withdrew the 2021 synthetic peptide guidance that underpinned the field. Here is what changed on impurities, higher order structure and immunogenicity testing.
ResearchSamsung Biologics' $1.8B bid for PolyPeptide is the latest in a wave of peptide capacity deals. Inside the GLP-1 demand shock, SPPS economics, purification bottlenecks and why CDMO capacity became a strategic asset.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides